All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional.

The Psoriasis and Psoriatic Arthritis Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

The Psoriasis and Psoriatic Arthritis Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Psoriasis and Psoriatic Arthritis Hub cannot guarantee the accuracy of translated content. The Psoriasis and Psoriatic Arthritis Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact

Visual abstract | A phase IV trial of apremilast in patients with special area involvement in plaque psoriasis (EMBRACE)

Mar 7, 2023
Learning objective: After reading this article, learners will be able to cite a new development in psoriasis.

The Psoriasis and Psoriatic Arthritis Hub is pleased to present a visual abstract representing key data from the phase IV EMBRACE trial (NCT03774875), which investigated the efficacy and safety of apremilast in patients with plaque psoriasis and involvement of at least one special area (dorsal hand, face, neck or hairline, scalp, nails, genital areas, or palmoplantar areas). This was a randomized, placebo-controlled trial, which compared apremilast 30 mg twice daily for 16 weeks to placebo.1

We have previously published a visual abstract on the use of apremilast in patients with mild-moderate plaque psoriasis (the ADVANCE trial) and an article about the 5-year safety of apremilast in psoriasis and psoriatic arthritis.

Visual abstract

To download this visual abstract, click below.

Download here

  1. Mrowietz U, Barker J, Conrad C, et al. Efficacy and safety of apremilast in patients with limited skin involvement, plaque psoriasis in special areas and impaired quality of life: Results from the EMBRACE randomized trial. J Eur Acad Dermatol Venereol. 2023;37(2):348-355. DOI: 1111/jdv.18689


Subscribe to get the best content related to psoriasis and psoriatic arthritis delivered to your inbox